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improved long-term outcomes due to the nephrotoxic effect of CNI regimens. A siro-
limus-based CNI withdrawal regimen may maximize the likelihood of long-term graft 
and patient survival. The goal of this study is to evaluate the cost-effectiveness of 
sirolimus regimen (sirolimuscyclosporinewithdrawal at three-monthsteroid) com-
pared with tacrolimus  mycofenolate mofetil(MMF)  Steroid regimen, and cyclo-
sporine MMF  steroid regimen in renal transplant patients in Korea. METHODS:
A Markov model simulates costs and outcomes in a hypothetical cohort of renal
transplant patients for 20 years with 5% discount rate. The model contain ﬁ ve health 
states: patient with graft survival, patient with graft failure, patient with regraft sur-
vival, patient with regraft failure and patient death. Short and long-term outcomes 
and utility weights were obtained from published literature, and quality adjusted life
years (QALYs) were used as an effectiveness measure. Resource utilizations and direct 
costs were calculated with the Korean public institutional data and clinical expert 
opinions. Sensitivity analyses were performed on crucial parameters. RESULTS: Siro-
limus regimen costs US$144,894 for the 8.055 QALYs for 20 years treatment dura-
tion, whereas US$173,234 for 6.399 QALYs for tacrolimus, and US$151,286 for
5.567 QALYs for cyclosporine. Sirolimus regimen was shown to be dominant, as it 
was more efﬁ cacious in QALYs and less costly than tacrolimus and cyclosporine
regimen. The results from the sensitivity analysis showed that the results were quite
robust across most parameters. Cost effectiveness was most sensitive to model dura-
tion. CONCLUSIONS: Sirolimus regimen shows not only potential clinical beneﬁ ts
for long-term but also is expected to be cost-saving over a patient’s life compared with 
the most frequently prescribed CNI regimens in Korea.
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OBJECTIVES: This study was conducted to evaluate the cost-effectiveness of Fes-
oterodine compared with Tolterodine in the treatment of OAB in Korea. The evalua-
tion was performed from the perspective of the statutory health insurer who will cover 
the direct costs of the drug upon approval and from societal viewpoint, as well. 
METHODS: Through a systematic review of preceding literature, we ﬁ rstly ﬁ gured 
out the factors that determine the efﬁ cacy for Fesoterodine and Tolterodine and sec-
ondly investigated whether Fesoterodine decreases symptom of OAB patients from 
randomized comparative trials with various comorbidities. Since there is no clinical
dataset of Fesoterodine along with Tolterodine for OAB patients in Korea, this study 
indirectly adopted the determinants and probabilities from the clinical results in all
languages for OAB treatment in order to estimate the treatment outcomes of the
selected comparators, and conducted the probabilistic sensitivity analysis. This study
also used to explore the cost-effectiveness of Fesoterodine in the following comorbidi-
ties: fracture, UTI, and depression. RESULTS: Based on the computed clinical success 
at week 12 of OAB treatment, Fesoterodine has higher performance than Tolterodine
by 18.44% point (56.50% vs. 38.06%) with a bit more total medical cost, though
(KRW 306,855 vs. KRW 260,457). In terms of cost-effectiveness ratio (CER), Fes-
oterodine has lower value than Tolterodine (KRW 5,431 vs. KRW 6,843), which 
implies that Fesoterodine is more cost-effective than Tolterodine in OAB treatment. 
Through the one-way sensitivity analysis varying the values of several controversial 
parameters such as resolution of incontinence, pad usage and frequency, and unit price
of pad, we could not ﬁ nd the reversal case in which Tolterodine outweighs Fesotero-
dine. CONCLUSIONS: Probabilistic analysis showed that OAB treatment with Fes-
oterodine is cost-effective in Korea compared to Tolterodine.
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OBJECTIVES: Overactive bladder (OAB) is a dysfunction of the lower urinary tract 
which causes signiﬁ cant impairment to patients’ QoL. Our study aim was to assess
the cost-effectiveness proﬁ le of Sacral neuromodulation (SNM), botulinum neurotoxin
(BoNT) and optimized medical treatment (OMT) in symptomatic idiopathic OAB 
patients with OMT experience in Spain. METHODS: A decision-analytic model was
built to simulate the clinical and economic consequences of initiating treatment for 
idiopathic OAB with SNM, BoNT or continue with OMT. Effectiveness (deﬁ ned in
terms of ‘improvement’, number of urinary incontinence episode and utility values) 
and model probabilities were obtained from literature; treatment pathways after initial
failure, resource use and assumptions were derived from local expert opinion. Due to
the lack of mid-long term efﬁ cacy data of BoNT, the most conservative assumptions
were included. The model was adjusted for a ten-year follow-up, to include the
neurostimulator battery change for SNM. Costs and effects were discounted at 3%.
RESULTS: OAB management with SNM may be associated with €12.18 and €2.62 
and per episode avoided and incremental cost-effectiveness ratios (ICERs) of 23,570€
and 1,573€ per Quality Adjusted Life Years (QALY) gained compared to OMT, at 
1 and 10 years respectively. SNM may also have a higher mid-long term effectiveness 
than BoNT at a reasonable cost, with ICERs of €29,450 and 9,287€ per QALY gained
at year 4 and 10, respectively. Probabilistic sensitivity analysis showed the robustness
of the results in SNM vs OMT, and due to the lack of BoNT efﬁ cacy data availability, 
an important variability in the results of SNM vs BoNT. CONCLUSIONS: SNM is 
effective in the treatment of OAB at a reasonable cost versus BoNT and OMT in
Spain. Further research is needed to assess the BoNT mid-long term effectiveness to
conﬁ rm the comparison versus SNM.
PUK13
COST-EFFECTIVENESS OF A RENAL HEALTH PROGRAM IN PATIENTS 
WITH HYPERTENSIVE AND/OR DIABETES INDUCED CHRONIC 
KIDNEY DISEASE
Rosselli D1, DeAntonio R2, Calderon C3, Sanabria M4
1Independiente, Bogotá, DC, Colombia, 2Independent, Bogota, Colombia, 3Independiente, 
Bogota, Colombia, 4Baxter Colombia, Bogota, Cundinamarca, Colombia
OBJECTIVES: To evaluate the impact of a hypothetical renal health program (RHP) 
designed to delay initiation of renal replacement therapy (RRT). METHODS: We 
used a Markov model and Monte Carlo technique to simulate two simultaneous 1000 
patient cohorts assigned to a renal health program (RHP) or to “standard care” (SC). 
Population consisted of patients with hypertension and/or diabetes, with initial 
glomerular ﬁ ltration rate (GFR) between 60 and 15 ml min (stages 3 and 4 of 
chronic kidney disease [CKD]). We assumed that RHP had a monthly cost of two 
to four times that of SC, and that it reduced GFR loss in a proportion that we
called “the RHP effect”. The model incorporated 47 variables: 20 epidemiologic
variables, 19 cost variables (all at local Colombian rates) and 8 quality of life variables
(we used QALY established through experts’ consensus). We used a third-party
payer perspective, a 5-year time frame and a 3% annual discount rate both for 
costs and for utilities. RESULTS: Assuming a RHP 0.8 effect (equivalent to a 20%
GFR loss reduction) the average cost per patient was US$ 17,680 in RHP and US$ 
15,560 in SC. Average utility was higher in RHP (3.53 QALY) than in SC (3.45 
QALY). From the total of 1000 patients of the RHP group, 101 died compared with 
124 in the SC group. Additionally, along the ﬁ ve-year period, 242 subjects from the
RHP group required RRT compared with 310 from the SC group. Based on these
results, US$ 90,950 would be paid per death averted, US$ 27,200 per RRT averted 
and the incremental cost-effectiveness ratio would be US$ 21,450 per QALY gained. 
CONCLUSIONS: Five years is a short time. Return to investment would be seen only
in patients with advanced CKD. However, a RHP with a modest effect would still de 
cost-effective.
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OBJECTIVES: To determine the effects of oxybutynin chloride topical gel (OTG), a 
novel 10% ethanolic formulation, on health-related quality of life (HRQoL) in adults 
with overactive bladder (OAB). METHODS: Women and men aged q18 years with 
urge urinary incontinence were enrolled at 76 centers in a randomized, double-blind,
placebo-controlled, parallel-group study (00350636 at clinicaltrials.gov). Patients 
applied 1 g OTG once daily or matching placebo gel for up to 12 weeks. To assess 
HRQoL, investigators asked patients to complete 2 disease-speciﬁ c questionnaires
(Incontinence Impact Questionnaire [IIQ]; King’s Health Questionnaire [KHQ]) at 
baseline and weeks 1, 4, 8, and 12. Effects of OTG on HRQoL were assessed by 
computing mean change in questionnaire scores from baseline to week 12 or last
observation. Differences between active and placebo treatment were compared by
analysis of covariance. RESULTS: In this study completed May 2007, 704 women and
85 men were enrolled; 389 patients received OTG and 400 received placebo. IIQ total 
score improved signiﬁ cantly more in patients treated with OTG (mean change, 72.1 
points; P  .0005) than in those receiving placebo (mean change, 49.5 points). OTG
also improved HRQoL signiﬁ cantly more (P a .0078) than did placebo in all 4 IIQ 
subscales (Travel, Physical Activity, Social Relationships, and Emotional Health). 
Mean KHQ scores improved signiﬁ cantly more (P a .0489) with OTG than with 
placebo in 6 of 10 domains, many directly associated with OAB symptoms (Inconti-
nence Impact, Symptom Severity, Role Limitations, Personal Relationships, Sleep/
Energy, and Severity [Coping] Measures). Dry mouth was the most common treat-
ment-related adverse event in patients given OTG (27/389; 6.9%), but was not a
primary reason for any patient to stop treatment. CONCLUSIONS: OTG treatment 
signiﬁ cantly improved HRQoL in adults with OAB.
